Literature DB >> 8295162

Abnormal speech articulation, psychomotor retardation, and subcortical dysfunction in major depression.

A J Flint1, S E Black, I Campbell-Taylor, G F Gailey, C Levinton.   

Abstract

Psychomotor retardation, characterized by changes in speech, motility and cognition, is common in major depression. It is also a cardinal feature of subcortical disorders such as Parkinson's disease (PD). Based on this observation and other data it has been hypothesized that the retardation of depression is related to mesolimbic-nigrostriatal dysfunction. To further test this hypothesis, speech articulation in major depression was compared to that in PD, where disordered articulation is related to bradykinesia and rigidity caused by striatal dopamine depletion. Thirty subjects with major depression were compared with 30 patients with PD and 31 normal controls on 3 acoustic measures of articulation. Major depression and PD groups had significantly shortened voice onset time and decreased second formant transition compared to controls, and major depression also had increased spirantization. There were no differences between the depression and PD groups on any of the acoustic measures. These findings provide indirect support for the hypothesis that nigrostriatal dysfunction is related to psychomotor slowing in major depression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8295162     DOI: 10.1016/0022-3956(93)90041-y

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  19 in total

1.  Emotion in speech: the acoustic attributes of fear, anger, sadness, and joy.

Authors:  C Sobin; M Alpert
Journal:  J Psycholinguist Res       Date:  1999-07

Review 2.  Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits.

Authors:  J D Salamone; M Correa; A Farrar; S M Mingote
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

Review 3.  Organization of brain somatomotor-sympathetic circuits.

Authors:  Ilan A Kerman
Journal:  Exp Brain Res       Date:  2008-03-28       Impact factor: 1.972

4.  Dyadic Behavior Analysis in Depression Severity Assessment Interviews.

Authors:  Stefan Scherer; Zakia Hammal; Ying Yang; Louis-Philippe Morency; Jeffrey F Cohn
Journal:  Proc ACM Int Conf Multimodal Interact       Date:  2014-11

5.  A Weakly Supervised Learning Framework for Detecting Social Anxiety and Depression.

Authors:  Asif Salekin; Jeremy W Eberle; Jeffrey J Glenn; Bethany A Teachman; John A Stankovic
Journal:  Proc ACM Interact Mob Wearable Ubiquitous Technol       Date:  2018-06

6.  Remote capture of human voice acoustical data by telephone: a methods study.

Authors:  Michael S Cannizzaro; Nicole Reilly; James C Mundt; Peter J Snyder
Journal:  Clin Linguist Phon       Date:  2005-12       Impact factor: 1.346

7.  Relationships among rat ultrasonic vocalizations, behavioral measures of striatal dopamine loss, and striatal tyrosine hydroxylase immunoreactivity at acute and chronic time points following unilateral 6-hydroxydopamine-induced dopamine depletion.

Authors:  Laura M Grant; David G Barnett; Emerald J Doll; Glen Leverson; Michelle Ciucci
Journal:  Behav Brain Res       Date:  2015-05-27       Impact factor: 3.332

8.  The Effect of Talker and Listener Depressive Symptoms on Speech Intelligibility.

Authors:  Hoyoung Yi; Rajka Smiljanic; Bharath Chandrasekaran
Journal:  J Speech Lang Hear Res       Date:  2019-11-18       Impact factor: 2.297

9.  Qualitative changes in ultrasonic vocalization in rats after unilateral dopamine depletion or haloperidol: a preliminary study.

Authors:  Michelle R Ciucci; Sean T Ma; Cynthia Fox; Jacqueline R Kane; Lorraine O Ramig; Timothy Schallert
Journal:  Behav Brain Res       Date:  2007-02-21       Impact factor: 3.332

Review 10.  Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression.

Authors:  Tomás Paus; Jennifer Barrett
Journal:  J Psychiatry Neurosci       Date:  2004-07       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.